Stock Scorecard

Stock Summary for Outlook Therapeutics Inc (OTLK) - $1.80 as of 5/30/2025 7:07:20 PM EST

Total Score

9 out of 30

Safety Score

37 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for OTLK

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OTLK

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OTLK

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for OTLK

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for OTLK (37 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 10
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for OTLK

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering 5/23/2025 10:30:00 AM
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - Outlook Therapeutics ( NASDAQ:OTLK ) 5/23/2025 10:30:00 AM
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD 4/8/2025 12:45:00 PM
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration 2/28/2025 1:05:00 PM
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , Bath & Body Works ( NYSE:BBWI ) 2/18/2025 1:44:00 PM
Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment 2/4/2025 2:05:00 PM
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors 1/31/2025 1:05:00 PM
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - Outlook Therapeutics ( NASDAQ:OTLK ) 1/31/2025 1:05:00 PM
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD 1/23/2025 2:05:00 PM
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar 1/22/2025 2:05:00 PM

Financial Details for OTLK

Company Overview
Ticker OTLK
Company Name Outlook Therapeutics Inc
Country USA
Description Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 1.80
Price 4 Years Ago 27.20
Last Day Price Updated 5/30/2025 7:07:20 PM EST
Last Day Volume 1,364,122
Average Daily Volume 524,412
52-Week High 9.25
52-Week Low 0.87
Last Price to 52 Week Low 106.90%

Valuation Measures
Trailing PE 0.40
Industry PE 59.99
Sector PE 40.42
5-Year Average PE -43.40
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio 19.17
Sector Free Cash Flow Ratio 31.66
Current Ratio Most Recent Quarter 0.72
Total Cash Per Share 176,328.14
Book Value Per Share Most Recent Quarter -0.99
Price to Book Ratio 10.19
Industry Price to Book Ratio 18.65
Sector Price to Book Ratio 29.96
Price to Sales Ratio Twelve Trailing Months 13.27
Industry Price to Sales Ratio Twelve Trailing Months 42.37
Sector Price to Sales Ratio Twelve Trailing Months 40.56
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 42,853,700
Market Capitalization 77,136,660
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -27.78%
Reported EPS 12 Trailing Months 4.09
Reported EPS Past Year -1.23
Reported EPS Prior Year -3.36
Net Income Twelve Trailing Months -46,357,138,521,918
Net Income Past Year -75,366,714
Net Income Prior Year -58,982,668
Quarterly Revenue Growth YOY 658.00%
5-Year Revenue Growth -53.87%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 7,556,313,000,000
Total Cash Past Year 14,927,538
Total Cash Prior Year 23,391,982
Net Cash Position Most Recent Quarter 7,556,291,955,000
Net Cash Position Past Year -14,512,462
Long Term Debt Past Year 29,440,000
Long Term Debt Prior Year 71,102,000
Total Debt Most Recent Quarter 21,045,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -73,076,510
Total Stockholder Equity Prior Year -14,437,777
Total Stockholder Equity Most Recent Quarter -32,462,605,000,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -27,551,108,949,239
Free Cash Flow Per Share Twelve Trailing Months -642,910.86
Free Cash Flow Past Year -68,793,858
Free Cash Flow Prior Year -42,973,400

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.04
MACD Signal 0.06
20-Day Bollinger Lower Band 1.13
20-Day Bollinger Middle Band 1.63
20-Day Bollinger Upper Band 2.13
Beta 0.39
RSI 53.65
50-Day SMA 4.12
150-Day SMA 13.34
200-Day SMA 18.63

System
Modified 5/29/2025 7:36:00 AM EST